Accessibility Menu
Rhythm Biosciences logo

Rhythm Biosciences(ASX) RHY

Market CapA$30.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-71%
5 Year-91%
1 Year-23%
1 Month-12%
A$0.08
-1.24%
-0.00Today
Rhythm Biosciences last closing stock price
MetricPriceDate
Last closeAUD 0.082026-08-13
Rhythm Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-11.96%AUD 0.092026-08-06
1 month-11.96%AUD 0.092026-07-14
3 month-42.96%AUD 0.142026-05-15
Year to date-40%AUD 0.142025-12-31
1 year-22.86%AUD 0.112025-08-13
3 year-79.75%AUD 0.402023-08-14
5 year-91.24%AUD 0.932021-08-13
Since inception-70.83%AUD 0.282017-12-07

Rhythm Biosciences Financials at a Glance

Market Cap

A$30.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$5.66M

Net Income (TTM)

-A$8.85M

EPS (TTM)

-A$0.02

P/E Ratio

-3.81

Dividend

A$0.00

Beta (Volatility)

-0.02 (Low)

Price

A$0.08

Volume

310,907

Open

A$0.08

Previous Close

A$0.08

Daily Range

A$0.08 - A$0.08

52-Week Range

A$0.08 - A$0.28

Estimated Earnings Date

Aug 27, 2026

RHY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rhythm Biosciences

Rhythm Biosciences Limited is a forward-thinking enterprise focused on predictive cancer diagnostics, operating in both Australian and global markets. The company specializes in the development and commercialization of innovative medical diagnostic technologies, with a key product being ColoSTAT, a blood test designed for the early detection of colorectal cancer.

Products and Services
  • ColoSTAT: A specialized blood test for colorectal cancer detection
  • Advanced diagnostic technologies aimed at improving cancer outcomes
  • Research and development in predictive diagnostics
Growth Outlook
  • Significant market potential in cancer diagnostics, projected to grow substantially
  • Recent advancements in ColoSTAT technology enhance competitive positioning
  • Strategic partnerships may accelerate product development and market entry
Financial Highlights
  • Recent quarterly revenue of AUD 46,247, showing growth potential
  • Cash and short-term investments increased to AUD 1,643,309
  • Operating cash flow improved, indicating better financial management
Rhythm Biosciences Limited is positioned in the healthcare sector, specifically within medical diagnostics and research. The company has made strides in developing its flagship product, ColoSTAT, which addresses a critical need in early cancer detection. The growth outlook remains promising, driven by the increasing demand for effective cancer diagnostics and the company's innovative approach to technology development. Recent financial data indicates a focus on improving cash flow and managing expenses, which may enhance the company's operational efficiency. As the market for cancer diagnostics continues to expand, Rhythm Biosciences is well-placed to capitalize on emerging opportunities.
AI Generated • Jul 22, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

CEO

David George Atkins, PhD, MBA

Website

www.rhythmbio.com

Headquarters

Parkville, VIC 3010, AU

RHY Financials

Key Financial Metrics (TTM)

Gross Margin

-6405.08%

Operating Margin

-11188.45%

Net Income Margin

-9353.35%

Return on Equity

-476.27%

Return on Capital

-199.92%

Return on Assets

-215.43%

Earnings Yield

-26.25%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$30.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

364.06M

Volume

310.91K

Avg. Volume

324.29K

Financials (TTM)

Gross Profit

-A$555.50K

Operating Income

-A$11.49M

EBITDA

-A$9.89M

Operating Cash Flow

-A$8.23M

Capital Expenditure

-A$25.82K

Free Cash Flow

-A$8.26M

Cash & ST Invst.

A$1.73M

Total Debt

A$262.44K

Rhythm Biosciences Performance Analysis

Rhythm Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 0N/A
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 25,126N/A
Rhythm Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3043.3%
Q22024-12-3130.8%
Q42025-06-30-99.2%
Q22025-12-3184.1%
Rhythm Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -0.04N/A
20232023-06-30AUD -0.04-9.5%
20242024-06-30AUD -0.03-19.1%
20252025-06-30AUD -0.01-52.7%
Rhythm Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3035.4%
Q22024-12-31119.7%
Q42025-06-30-778.3%
Q22025-12-3154.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$46.25K

-97.3%

Gross Profit

-A$2.14M

+16.7%

Gross Margin

-46.24%

N/A

Market Cap

A$30.95MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$1.35M

N/A

Employees

23

N/A

Net Income

-A$2.26M

+44.8%

EBITDA

-A$3.69M

+34.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$1.73M

+36.8%

Total Debt

A$262.44K

+574.0%

Accounts Receivable

A$61.39K

-19.8%

Inventory

A$73.29K

+1687.7%

Long Term Debt

A$0.00

N/A

Short Term Debt

A$262.44K

+237.0%

Return on Assets

-2.15%

N/A

Return on Invested Capital

-3.70%

N/A

Free Cash Flow

-A$2.22M

+29.0%

Operating Cash Flow

-A$2.22M

+27.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MAP.AXMicroba Life Sciences Limited
A$0.05+0.00%
IIQ.AXINOVIQ Ltd
A$0.19+0.00%
NOX.AXNoxopharm Limited
A$0.08+6.41%
OSL.AXOncoSil Medical Ltd
A$1.28+1.59%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About RHY

What is the current price of Rhythm Biosciences?

Rhythm Biosciences is trading at A$0.08 per share.

What is the 52-week range for Rhythm Biosciences?

Over the past 52 weeks, Rhythm Biosciences has traded between A$0.08 and A$0.28.

How much debt does Rhythm Biosciences have?

As of the most recent reporting period, Rhythm Biosciences reported total debt of A$1.11M.

How much cash does Rhythm Biosciences have on hand?

Rhythm Biosciences reported A$1.40M in cash and cash equivalents in its most recent financial results.

What is Rhythm Biosciences’s dividend yield?

Rhythm Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services